AstraZeneca is buying Fusion Pharmaceuticals, a Canadian company specializing in radioconjugation cancer treatments, for $2.4 billion.
Petru Nicolaescu
Health
Unsplash.com
Always see our news on Google
The acquisition of Fusion Pharmaceuticals by AstraZeneca brings innovative new treatments to the company's portfolio. Radioconjugates developed by Fusion are an alternative to chemotherapy and radiotherapy, minimizing damage to healthy cells. The most advanced treatment, FPI-2265, is for patients with metastatic prostate cancer.
Latest News
23:01
Ministry of Finance: Romania still has €6.43 billion to receive through the NRRP. The European Commission’s decision is expected by November 20
22:57
Approximately 6,800 minors detained in France amid protests at schools / Lawyers report possible abuses by law enforcement
22:53
Franța și Germania propun relaxarea țintei de emisii pentru mașinile noi din 2035 în schimbul unor reguli favorabile producției europene
22:50
The Commission will create a European coalition of companies against human trafficking
22:43
South-East and South-West Oltenia have 38% and 36% of their populations at risk of poverty or social exclusion
See more news
NEWS ON THE SAME TOPICS
International
AstraZeneca, negotiations with Bristol Myers Squibb for a possible merger that could create a 400 billion dollar group
IT&C knowledge
Novo collaborates with Anthropic to use artificial intelligence in the research and development of new medicines
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
